GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

The concomitant administration of multiple vaccines at a single ... post-vac Intergroup difference –5% Meningococcal hSBA titer ≥4 % of subjects with hSBA ≥1:8 or with seroresponse ...

Polio vaccine; varicella (Chickenpox) vaccine; meningococcal conjugate vaccine (MenACWY); booster doses of MenACWY; and the ...

Hundreds have already taken advantage of the CLP’s free meningococcal B vaccination program, which provides protection for infants aged six weeks to two years, and teens aged 14 to 19 years.